SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis

Background The temporal evolution of SARS-CoV-2 vaccine efficacy and effectiveness (VE) against infection, symptomatic, and severe COVID-19 is incompletely defined. The temporal evolution of VE could be dependent on age, vaccine types, variants of the virus, and geographic region. We aimed to conduc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMC infectious diseases Jg. 22; H. 1; S. 439 - 12
Hauptverfasser:	Ssentongo, Paddy, Ssentongo, Anna E., Voleti, Navya, Groff, Destin, Sun, Ashley, Ba, Djibril M., Nunez, Jonathan, Parent, Leslie J., Chinchilli, Vernon M., Paules, Catharine I.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London BioMed Central 07.05.2022 BioMed Central Ltd Springer Nature B.V BMC
Schlagworte:	Age Bias Clinical trials Coronaviruses COVID-19 COVID-19 vaccines Estimates Evolution Infections Infectious Diseases Internal Medicine Literature reviews Medical Microbiology Medicine Medicine & Public Health Meta-analysis mRNA vaccines Parasitology Public health Quality assessment Risk assessment Severe acute respiratory syndrome coronavirus 2 Tropical Medicine Vaccination Vaccine effectiveness Vaccine efficacy Vaccines Viral diseases Waning immunity Web portals United States United States > US COVID-19 Waning immunity Vaccine effectiveness
ISSN:	1471-2334, 1471-2334
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Background The temporal evolution of SARS-CoV-2 vaccine efficacy and effectiveness (VE) against infection, symptomatic, and severe COVID-19 is incompletely defined. The temporal evolution of VE could be dependent on age, vaccine types, variants of the virus, and geographic region. We aimed to conduct a systematic review and meta-analysis of the duration of VE against SARS-CoV-2 infection, symptomatic COVID-19 and severe COVID-19. Methods MEDLINE, Scopus, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, the World Health Organization Global Literature on Coronavirus Disease, and CoronaCentral databases were searched and studies were selected. Independent reviewers selected randomized controlled trials and cohort studies with the outcome of interest. Independent reviewers extracted data, and assessed the risk of bias. Meta-analysis was performed with the DerSimonian-Laird random-effects model with Hartung-Knapp-Sidik-Jonkman variance correction. The GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach was used to assess certainty (quality) of the evidence. Primary outcomes included VE as a function of time against SARS-CoV-2 infection, symptomatic and severe COVID-19. Results Eighteen studies were included representing nearly 7 million individuals. VE against all SARS-CoV-2 infections declined from 83% in the first month after completion of the original vaccination series to 22% at 5 months or longer. Similarly, VE against symptomatic COVID-19 declined from 94% in the first month after vaccination to 64% by the fourth month. VE against severe COVID-19 for all ages was high overall, with the level being 90% (95% CI, 87–92%) at five months or longer after being fully vaccinated. VE against severe COVID-19 was lower in individuals ≥ 65 years and those who received Ad26.COV2.S. Conclusions VE against SARS-CoV-2 infection and symptomatic COVID-19 waned over time but protection remained high against severe COVID-19. These data can be used to inform public health decisions around the need for booster vaccination.
AbstractList	The temporal evolution of SARS-CoV-2 vaccine efficacy and effectiveness (VE) against infection, symptomatic, and severe COVID-19 is incompletely defined. The temporal evolution of VE could be dependent on age, vaccine types, variants of the virus, and geographic region. We aimed to conduct a systematic review and meta-analysis of the duration of VE against SARS-CoV-2 infection, symptomatic COVID-19 and severe COVID-19. MEDLINE, Scopus, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, the World Health Organization Global Literature on Coronavirus Disease, and CoronaCentral databases were searched and studies were selected. Independent reviewers selected randomized controlled trials and cohort studies with the outcome of interest. Independent reviewers extracted data, and assessed the risk of bias. Meta-analysis was performed with the DerSimonian-Laird random-effects model with Hartung-Knapp-Sidik-Jonkman variance correction. The GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach was used to assess certainty (quality) of the evidence. Primary outcomes included VE as a function of time against SARS-CoV-2 infection, symptomatic and severe COVID-19. Eighteen studies were included representing nearly 7 million individuals. VE against all SARS-CoV-2 infections declined from 83% in the first month after completion of the original vaccination series to 22% at 5 months or longer. Similarly, VE against symptomatic COVID-19 declined from 94% in the first month after vaccination to 64% by the fourth month. VE against severe COVID-19 for all ages was high overall, with the level being 90% (95% CI, 87-92%) at five months or longer after being fully vaccinated. VE against severe COVID-19 was lower in individuals ≥ 65 years and those who received Ad26.COV2.S. VE against SARS-CoV-2 infection and symptomatic COVID-19 waned over time but protection remained high against severe COVID-19. These data can be used to inform public health decisions around the need for booster vaccination. Background The temporal evolution of SARS-CoV-2 vaccine efficacy and effectiveness (VE) against infection, symptomatic, and severe COVID-19 is incompletely defined. The temporal evolution of VE could be dependent on age, vaccine types, variants of the virus, and geographic region. We aimed to conduct a systematic review and meta-analysis of the duration of VE against SARS-CoV-2 infection, symptomatic COVID-19 and severe COVID-19. Methods MEDLINE, Scopus, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, the World Health Organization Global Literature on Coronavirus Disease, and CoronaCentral databases were searched and studies were selected. Independent reviewers selected randomized controlled trials and cohort studies with the outcome of interest. Independent reviewers extracted data, and assessed the risk of bias. Meta-analysis was performed with the DerSimonian-Laird random-effects model with Hartung-Knapp-Sidik-Jonkman variance correction. The GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach was used to assess certainty (quality) of the evidence. Primary outcomes included VE as a function of time against SARS-CoV-2 infection, symptomatic and severe COVID-19. Results Eighteen studies were included representing nearly 7 million individuals. VE against all SARS-CoV-2 infections declined from 83% in the first month after completion of the original vaccination series to 22% at 5 months or longer. Similarly, VE against symptomatic COVID-19 declined from 94% in the first month after vaccination to 64% by the fourth month. VE against severe COVID-19 for all ages was high overall, with the level being 90% (95% CI, 87–92%) at five months or longer after being fully vaccinated. VE against severe COVID-19 was lower in individuals ≥ 65 years and those who received Ad26.COV2.S. Conclusions VE against SARS-CoV-2 infection and symptomatic COVID-19 waned over time but protection remained high against severe COVID-19. These data can be used to inform public health decisions around the need for booster vaccination. The temporal evolution of SARS-CoV-2 vaccine efficacy and effectiveness (VE) against infection, symptomatic, and severe COVID-19 is incompletely defined. The temporal evolution of VE could be dependent on age, vaccine types, variants of the virus, and geographic region. We aimed to conduct a systematic review and meta-analysis of the duration of VE against SARS-CoV-2 infection, symptomatic COVID-19 and severe COVID-19.BACKGROUNDThe temporal evolution of SARS-CoV-2 vaccine efficacy and effectiveness (VE) against infection, symptomatic, and severe COVID-19 is incompletely defined. The temporal evolution of VE could be dependent on age, vaccine types, variants of the virus, and geographic region. We aimed to conduct a systematic review and meta-analysis of the duration of VE against SARS-CoV-2 infection, symptomatic COVID-19 and severe COVID-19.MEDLINE, Scopus, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, the World Health Organization Global Literature on Coronavirus Disease, and CoronaCentral databases were searched and studies were selected. Independent reviewers selected randomized controlled trials and cohort studies with the outcome of interest. Independent reviewers extracted data, and assessed the risk of bias. Meta-analysis was performed with the DerSimonian-Laird random-effects model with Hartung-Knapp-Sidik-Jonkman variance correction. The GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach was used to assess certainty (quality) of the evidence. Primary outcomes included VE as a function of time against SARS-CoV-2 infection, symptomatic and severe COVID-19.METHODSMEDLINE, Scopus, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, the World Health Organization Global Literature on Coronavirus Disease, and CoronaCentral databases were searched and studies were selected. Independent reviewers selected randomized controlled trials and cohort studies with the outcome of interest. Independent reviewers extracted data, and assessed the risk of bias. Meta-analysis was performed with the DerSimonian-Laird random-effects model with Hartung-Knapp-Sidik-Jonkman variance correction. The GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach was used to assess certainty (quality) of the evidence. Primary outcomes included VE as a function of time against SARS-CoV-2 infection, symptomatic and severe COVID-19.Eighteen studies were included representing nearly 7 million individuals. VE against all SARS-CoV-2 infections declined from 83% in the first month after completion of the original vaccination series to 22% at 5 months or longer. Similarly, VE against symptomatic COVID-19 declined from 94% in the first month after vaccination to 64% by the fourth month. VE against severe COVID-19 for all ages was high overall, with the level being 90% (95% CI, 87-92%) at five months or longer after being fully vaccinated. VE against severe COVID-19 was lower in individuals ≥ 65 years and those who received Ad26.COV2.S.RESULTSEighteen studies were included representing nearly 7 million individuals. VE against all SARS-CoV-2 infections declined from 83% in the first month after completion of the original vaccination series to 22% at 5 months or longer. Similarly, VE against symptomatic COVID-19 declined from 94% in the first month after vaccination to 64% by the fourth month. VE against severe COVID-19 for all ages was high overall, with the level being 90% (95% CI, 87-92%) at five months or longer after being fully vaccinated. VE against severe COVID-19 was lower in individuals ≥ 65 years and those who received Ad26.COV2.S.VE against SARS-CoV-2 infection and symptomatic COVID-19 waned over time but protection remained high against severe COVID-19. These data can be used to inform public health decisions around the need for booster vaccination.CONCLUSIONSVE against SARS-CoV-2 infection and symptomatic COVID-19 waned over time but protection remained high against severe COVID-19. These data can be used to inform public health decisions around the need for booster vaccination. The temporal evolution of SARS-CoV-2 vaccine efficacy and effectiveness (VE) against infection, symptomatic, and severe COVID-19 is incompletely defined. The temporal evolution of VE could be dependent on age, vaccine types, variants of the virus, and geographic region. We aimed to conduct a systematic review and meta-analysis of the duration of VE against SARS-CoV-2 infection, symptomatic COVID-19 and severe COVID-19. MEDLINE, Scopus, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, the World Health Organization Global Literature on Coronavirus Disease, and CoronaCentral databases were searched and studies were selected. Independent reviewers selected randomized controlled trials and cohort studies with the outcome of interest. Independent reviewers extracted data, and assessed the risk of bias. Meta-analysis was performed with the DerSimonian-Laird random-effects model with Hartung-Knapp-Sidik-Jonkman variance correction. The GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach was used to assess certainty (quality) of the evidence. Primary outcomes included VE as a function of time against SARS-CoV-2 infection, symptomatic and severe COVID-19. Eighteen studies were included representing nearly 7 million individuals. VE against all SARS-CoV-2 infections declined from 83% in the first month after completion of the original vaccination series to 22% at 5 months or longer. Similarly, VE against symptomatic COVID-19 declined from 94% in the first month after vaccination to 64% by the fourth month. VE against severe COVID-19 for all ages was high overall, with the level being 90% (95% CI, 87-92%) at five months or longer after being fully vaccinated. VE against severe COVID-19 was lower in individuals [greater than or equai to] 65 years and those who received Ad26.COV2.S. VE against SARS-CoV-2 infection and symptomatic COVID-19 waned over time but protection remained high against severe COVID-19. These data can be used to inform public health decisions around the need for booster vaccination. Background The temporal evolution of SARS-CoV-2 vaccine efficacy and effectiveness (VE) against infection, symptomatic, and severe COVID-19 is incompletely defined. The temporal evolution of VE could be dependent on age, vaccine types, variants of the virus, and geographic region. We aimed to conduct a systematic review and meta-analysis of the duration of VE against SARS-CoV-2 infection, symptomatic COVID-19 and severe COVID-19. Methods MEDLINE, Scopus, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, the World Health Organization Global Literature on Coronavirus Disease, and CoronaCentral databases were searched and studies were selected. Independent reviewers selected randomized controlled trials and cohort studies with the outcome of interest. Independent reviewers extracted data, and assessed the risk of bias. Meta-analysis was performed with the DerSimonian-Laird random-effects model with Hartung-Knapp-Sidik-Jonkman variance correction. The GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach was used to assess certainty (quality) of the evidence. Primary outcomes included VE as a function of time against SARS-CoV-2 infection, symptomatic and severe COVID-19. Results Eighteen studies were included representing nearly 7 million individuals. VE against all SARS-CoV-2 infections declined from 83% in the first month after completion of the original vaccination series to 22% at 5 months or longer. Similarly, VE against symptomatic COVID-19 declined from 94% in the first month after vaccination to 64% by the fourth month. VE against severe COVID-19 for all ages was high overall, with the level being 90% (95% CI, 87–92%) at five months or longer after being fully vaccinated. VE against severe COVID-19 was lower in individuals ≥ 65 years and those who received Ad26.COV2.S. Conclusions VE against SARS-CoV-2 infection and symptomatic COVID-19 waned over time but protection remained high against severe COVID-19. These data can be used to inform public health decisions around the need for booster vaccination. Abstract Background The temporal evolution of SARS-CoV-2 vaccine efficacy and effectiveness (VE) against infection, symptomatic, and severe COVID-19 is incompletely defined. The temporal evolution of VE could be dependent on age, vaccine types, variants of the virus, and geographic region. We aimed to conduct a systematic review and meta-analysis of the duration of VE against SARS-CoV-2 infection, symptomatic COVID-19 and severe COVID-19. Methods MEDLINE, Scopus, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, the World Health Organization Global Literature on Coronavirus Disease, and CoronaCentral databases were searched and studies were selected. Independent reviewers selected randomized controlled trials and cohort studies with the outcome of interest. Independent reviewers extracted data, and assessed the risk of bias. Meta-analysis was performed with the DerSimonian-Laird random-effects model with Hartung-Knapp-Sidik-Jonkman variance correction. The GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach was used to assess certainty (quality) of the evidence. Primary outcomes included VE as a function of time against SARS-CoV-2 infection, symptomatic and severe COVID-19. Results Eighteen studies were included representing nearly 7 million individuals. VE against all SARS-CoV-2 infections declined from 83% in the first month after completion of the original vaccination series to 22% at 5 months or longer. Similarly, VE against symptomatic COVID-19 declined from 94% in the first month after vaccination to 64% by the fourth month. VE against severe COVID-19 for all ages was high overall, with the level being 90% (95% CI, 87–92%) at five months or longer after being fully vaccinated. VE against severe COVID-19 was lower in individuals ≥ 65 years and those who received Ad26.COV2.S. Conclusions VE against SARS-CoV-2 infection and symptomatic COVID-19 waned over time but protection remained high against severe COVID-19. These data can be used to inform public health decisions around the need for booster vaccination. Background The temporal evolution of SARS-CoV-2 vaccine efficacy and effectiveness (VE) against infection, symptomatic, and severe COVID-19 is incompletely defined. The temporal evolution of VE could be dependent on age, vaccine types, variants of the virus, and geographic region. We aimed to conduct a systematic review and meta-analysis of the duration of VE against SARS-CoV-2 infection, symptomatic COVID-19 and severe COVID-19. Methods MEDLINE, Scopus, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, the World Health Organization Global Literature on Coronavirus Disease, and CoronaCentral databases were searched and studies were selected. Independent reviewers selected randomized controlled trials and cohort studies with the outcome of interest. Independent reviewers extracted data, and assessed the risk of bias. Meta-analysis was performed with the DerSimonian-Laird random-effects model with Hartung-Knapp-Sidik-Jonkman variance correction. The GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach was used to assess certainty (quality) of the evidence. Primary outcomes included VE as a function of time against SARS-CoV-2 infection, symptomatic and severe COVID-19. Results Eighteen studies were included representing nearly 7 million individuals. VE against all SARS-CoV-2 infections declined from 83% in the first month after completion of the original vaccination series to 22% at 5 months or longer. Similarly, VE against symptomatic COVID-19 declined from 94% in the first month after vaccination to 64% by the fourth month. VE against severe COVID-19 for all ages was high overall, with the level being 90% (95% CI, 87-92%) at five months or longer after being fully vaccinated. VE against severe COVID-19 was lower in individuals [greater than or equai to] 65 years and those who received Ad26.COV2.S. Conclusions VE against SARS-CoV-2 infection and symptomatic COVID-19 waned over time but protection remained high against severe COVID-19. These data can be used to inform public health decisions around the need for booster vaccination. Keywords: Vaccine effectiveness, COVID-19, Waning immunity
ArticleNumber	439
Audience	Academic
Author	Groff, Destin Paules, Catharine I. Voleti, Navya Sun, Ashley Ba, Djibril M. Parent, Leslie J. Nunez, Jonathan Chinchilli, Vernon M. Ssentongo, Paddy Ssentongo, Anna E.
Author_xml	– sequence: 1 givenname: Paddy surname: Ssentongo fullname: Ssentongo, Paddy email: pssentongo@pennstatehealth.psu.edu organization: Department of Public Health Sciences, Penn State College of Medicine and Milton S. Hershey Medical Center, Department of Medicine, Penn State College of Medicine and Milton S. Hershey Medical Center – sequence: 2 givenname: Anna E. surname: Ssentongo fullname: Ssentongo, Anna E. organization: Department of Public Health Sciences, Penn State College of Medicine and Milton S. Hershey Medical Center, Department of Surgery, Penn State College of Medicine and Milton S. Hershey Medical Center – sequence: 3 givenname: Navya surname: Voleti fullname: Voleti, Navya organization: Department of Medicine, Penn State College of Medicine and Milton S. Hershey Medical Center – sequence: 4 givenname: Destin surname: Groff fullname: Groff, Destin organization: Penn State College of Medicine – sequence: 5 givenname: Ashley surname: Sun fullname: Sun, Ashley organization: Penn State College of Medicine – sequence: 6 givenname: Djibril M. surname: Ba fullname: Ba, Djibril M. organization: Department of Public Health Sciences, Penn State College of Medicine and Milton S. Hershey Medical Center – sequence: 7 givenname: Jonathan surname: Nunez fullname: Nunez, Jonathan organization: Division of Infectious Diseases and Epidemiology, Department of Medicine, Penn State Hershey College of Medicine and Milton S. Hershey Medical Center – sequence: 8 givenname: Leslie J. surname: Parent fullname: Parent, Leslie J. organization: Division of Infectious Diseases and Epidemiology, Departments of Medicine and Microbiology and Immunology, Penn State College of Medicine – sequence: 9 givenname: Vernon M. surname: Chinchilli fullname: Chinchilli, Vernon M. organization: Department of Public Health Sciences, Penn State College of Medicine and Milton S. Hershey Medical Center – sequence: 10 givenname: Catharine I. surname: Paules fullname: Paules, Catharine I. organization: Division of Infectious Diseases and Epidemiology, Department of Medicine, Penn State Hershey College of Medicine and Milton S. Hershey Medical Center
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/35525973$$D View this record in MEDLINE/PubMed
BookMark	eNqNkl1v0zAUhiM0xLbCH-ACReIGJDL8ldjhAqkqX5UmVVqht5bjnARXiV1it1B-PW67sXVCE8qFo-PnfX18_J4nJ9ZZSJLnGF1gLIq3HhPBywwRkiHOsMi2j5IzzDjOCKXs5M7_aXLu_RIhzAUpnySnNM9JXnJ6lvyej6_m2cQtMpJulNbGQgpNAzqYDVjwPlWtMtaH1Nh91dk3qd_2q-B6FYxOla1TDxsYIJ3MFtMPGS7fpSoiPsCBGGBj4Oce7CGoTFnVbb3xT5PHjeo8PLteR8m3Tx-_Tr5kl7PP08n4MtMFz0NWYyQqTgCEaEjJtMoRJgpQTYtK1RwIqUleYU54w1ldNhgBY5QQXjHCalHQUTI9-NZOLeVqML0attIpI_cFN7RSDbHRDiRVRVUijJAoEEOoVpVmu0OpoLoqChS93h-8Vuuqh1qDDYPqjkyPd6z5Llu3kSXinMa-Rsmra4PB_ViDD7I3XkPXKQtu7SUpinjfglAc0Zf30KVbD3F4e6pgqCQC3VKtiheIj-TiuXpnKsccERGxcud18Q8qfjX0RsdYNSbWjwSvjwSRCfArtGrtvZzOr_6fnS2O2Rd3B_h3cjeJjIA4AHpw3g_QSG2C2uUudmw6iZHchV8ewi9j-OU-_HIbpeSe9Mb9QRE9iHyEbQvD7ZQfUP0BynQTBQ
CitedBy_id	crossref_primary_10_1016_j_vaccine_2023_10_032 crossref_primary_10_3389_fimmu_2023_1123158 crossref_primary_10_1177_03946320231189993 crossref_primary_10_3390_vaccines11091424 crossref_primary_10_1016_j_vaccine_2024_04_049 crossref_primary_10_1002_ajim_23458 crossref_primary_10_1016_j_cmi_2025_07_026 crossref_primary_10_1007_s15010_024_02187_z crossref_primary_10_1016_j_puhe_2022_11_002 crossref_primary_10_1038_s41598_024_80465_4 crossref_primary_10_3390_vaccines11051011 crossref_primary_10_4103_ijpvm_ijpvm_260_24 crossref_primary_10_2478_tmmp_2024_0026 crossref_primary_10_3390_vaccines10121997 crossref_primary_10_1016_j_vaccine_2022_09_019 crossref_primary_10_1007_s00285_024_02111_x crossref_primary_10_1038_s41598_023_50756_3 crossref_primary_10_1038_s41467_022_33460_0 crossref_primary_10_3390_v14122771 crossref_primary_10_1002_pca_3462 crossref_primary_10_1007_s11356_022_22661_1 crossref_primary_10_1186_s12879_025_10692_1 crossref_primary_10_1093_biomethods_bpae095 crossref_primary_10_1136_bmjgh_2023_012328 crossref_primary_10_1007_s43440_023_00519_8 crossref_primary_10_3390_tropicalmed9030061 crossref_primary_10_3390_vaccines12020163 crossref_primary_10_1007_s42770_024_01507_7 crossref_primary_10_1093_aje_kwae280 crossref_primary_10_1038_s41467_024_46536_w crossref_primary_10_3389_fimmu_2023_1163159 crossref_primary_10_1016_j_jviromet_2023_114835 crossref_primary_10_2174_0115680266325847241121034100 crossref_primary_10_1002_ctm2_1171 crossref_primary_10_1177_22799036231181852 crossref_primary_10_1136_bmjopen_2023_072650 crossref_primary_10_1016_j_jinf_2023_08_009 crossref_primary_10_3390_ijms23147675 crossref_primary_10_3390_vaccines12030230 crossref_primary_10_1038_s41541_023_00630_0 crossref_primary_10_1038_s41598_023_47043_6 crossref_primary_10_1007_s10238_023_01223_w crossref_primary_10_1007_s15010_024_02438_z crossref_primary_10_1016_j_jiac_2025_102660 crossref_primary_10_2147_OAJCT_S471245 crossref_primary_10_1016_j_beha_2022_101384 crossref_primary_10_1007_s11936_023_01008_0 crossref_primary_10_1007_s40121_023_00891_1 crossref_primary_10_1093_infdis_jiac458 crossref_primary_10_1016_j_clicom_2025_07_001 crossref_primary_10_3389_fpubh_2023_1218188 crossref_primary_10_3389_fpubh_2024_1422673 crossref_primary_10_1186_s12879_023_08407_5 crossref_primary_10_3390_biotech13030022 crossref_primary_10_1186_s13690_025_01537_z crossref_primary_10_1186_s12963_025_00398_6 crossref_primary_10_1371_journal_pone_0320779 crossref_primary_10_1016_j_lanwpc_2023_100930 crossref_primary_10_1055_a_2665_2400 crossref_primary_10_1136_bmjopen_2023_073555 crossref_primary_10_1186_s12879_023_08869_7 crossref_primary_10_1038_s41541_023_00665_3 crossref_primary_10_3390_jcm11206060 crossref_primary_10_1097_EDE_0000000000001846 crossref_primary_10_2807_1560_7917_ES_2025_30_8_2400450 crossref_primary_10_24171_j_phrp_2023_0096 crossref_primary_10_1016_j_vaccine_2025_126966 crossref_primary_10_1016_j_bios_2023_115423 crossref_primary_10_1016_j_virs_2024_08_003 crossref_primary_10_1093_aje_kwae303 crossref_primary_10_1016_j_lanmic_2024_100984 crossref_primary_10_1136_rmdopen_2024_005138 crossref_primary_10_1016_j_jconrel_2025_113891 crossref_primary_10_2903_j_efsa_2023_7822 crossref_primary_10_3390_idr14060101 crossref_primary_10_3389_fimmu_2022_1031852 crossref_primary_10_1038_s41598_023_47611_w crossref_primary_10_1590_1519_6984_279691 crossref_primary_10_3389_fmed_2023_1155727 crossref_primary_10_3390_vaccines11030507 crossref_primary_10_1001_jamanetworkopen_2024_59672 crossref_primary_10_1002_sim_70260 crossref_primary_10_3389_fimmu_2023_1150667 crossref_primary_10_1097_MD_0000000000035360 crossref_primary_10_1016_j_heliyon_2024_e40124 crossref_primary_10_1111_eci_14325 crossref_primary_10_1038_s41408_022_00778_3 crossref_primary_10_1038_s41586_022_05398_2 crossref_primary_10_1089_derm_2023_0210 crossref_primary_10_3390_ijerph191912422 crossref_primary_10_3390_vaccines12010039 crossref_primary_10_3389_fimmu_2022_965971 crossref_primary_10_3390_vaccines10111866 crossref_primary_10_1038_s41598_022_26202_1 crossref_primary_10_3390_vaccines10091497 crossref_primary_10_3390_vaccines11091461 crossref_primary_10_1371_journal_pone_0304110 crossref_primary_10_3390_pharmaceutics16111423 crossref_primary_10_3389_fimmu_2023_1185278 crossref_primary_10_1136_bmjopen_2023_072280 crossref_primary_10_3389_fimmu_2022_1079884 crossref_primary_10_1007_s12026_023_09449_2 crossref_primary_10_1016_j_vaccine_2023_11_032 crossref_primary_10_1016_j_jiac_2022_12_009 crossref_primary_10_1186_s12879_024_09680_8 crossref_primary_10_3390_diagnostics13111888 crossref_primary_10_1007_s10815_025_03403_x crossref_primary_10_1016_j_bbih_2023_100722 crossref_primary_10_1016_j_vaccine_2025_127476 crossref_primary_10_1007_s40121_022_00753_2 crossref_primary_10_1097_TP_0000000000004411 crossref_primary_10_1111_bjh_18726 crossref_primary_10_1016_j_heliyon_2023_e20009 crossref_primary_10_1126_sciimmunol_add3075 crossref_primary_10_1016_j_arcmed_2022_10_007 crossref_primary_10_3390_vaccines12060669 crossref_primary_10_1038_s41598_024_80636_3 crossref_primary_10_3390_jcm12062420 crossref_primary_10_3390_vaccines12030315 crossref_primary_10_1007_s00467_022_05736_6 crossref_primary_10_1016_j_epidem_2023_100730 crossref_primary_10_1016_j_jiac_2024_02_008 crossref_primary_10_1016_j_lanwpc_2023_100788 crossref_primary_10_1371_journal_pone_0294362 crossref_primary_10_3390_vaccines11061081 crossref_primary_10_1016_j_medcle_2024_09_001 crossref_primary_10_1055_a_2107_0891 crossref_primary_10_7759_cureus_80582 crossref_primary_10_1136_bmjopen_2023_076892 crossref_primary_10_7759_cureus_30286 crossref_primary_10_1080_14760584_2022_2102001 crossref_primary_10_1089_vim_2022_0186 crossref_primary_10_3390_v14081766 crossref_primary_10_3390_vaccines12101149 crossref_primary_10_1159_000534327 crossref_primary_10_3947_ic_2024_0128 crossref_primary_10_1089_hs_2023_0136 crossref_primary_10_3390_jcm11216464 crossref_primary_10_1186_s12916_023_03025_z crossref_primary_10_3390_v15061366 crossref_primary_10_1016_j_jiph_2023_09_012 crossref_primary_10_3389_fendo_2022_1027047 crossref_primary_10_1016_j_jiph_2022_11_028 crossref_primary_10_3389_fpubh_2023_1250911 crossref_primary_10_3389_fimmu_2023_1070077 crossref_primary_10_3390_hemato4020014 crossref_primary_10_3390_vaccines12030301 crossref_primary_10_1148_radiol_230454 crossref_primary_10_3390_vaccines12121350 crossref_primary_10_3390_ijms26062550 crossref_primary_10_1080_15265161_2023_2250282 crossref_primary_10_1186_s12879_024_09282_4 crossref_primary_10_3389_fpubh_2025_1598246 crossref_primary_10_3390_vaccines11010031 crossref_primary_10_4103_tcmj_tcmj_107_23 crossref_primary_10_3389_fimmu_2025_1557426 crossref_primary_10_3390_vaccines12060566 crossref_primary_10_3390_vaccines10122074 crossref_primary_10_1155_2024_7140548 crossref_primary_10_1007_s00296_022_05229_7 crossref_primary_10_3390_vaccines11030544 crossref_primary_10_1038_s41423_023_01116_8 crossref_primary_10_3389_fpubh_2023_950475 crossref_primary_10_3390_jcm11175019 crossref_primary_10_3390_vaccines12030254 crossref_primary_10_1128_jvi_01912_23 crossref_primary_10_3389_fcvm_2022_951314
Cites_doi	10.1136/bmj.n71 10.1016/S0140-6736(21)02249-2 10.1016/j.csda.2005.07.019 10.1056/NEJMc2114089 10.1056/NEJMoa2107456 10.1056/NEJMoa2119451 10.1016/j.cmi.2021.06.043 10.1056/NEJMoa2035389 10.1056/NEJMoa2101765 10.1056/NEJMoa2109522 10.1136/bmj.39489.470347.AD 10.1056/NEJMoa2113017 10.1001/jama.2021.19499 10.15585/mmwr.mm7037e1 10.1002/9780470712184.ch8 10.1056/NEJMoa2034577 10.1136/bmj.315.7109.629 10.1016/S0140-6736(21)02183-8 10.15585/mmwr.mm7038e1 10.1016/S0140-6736(21)00947-8 10.1136/bmj.327.7414.557 10.1056/NEJMoa2110345 10.1056/NEJMoa2114255 10.1016/j.vaccine.2019.10.090 10.1016/S0140-6736(21)00790-X 10.1186/s12913-014-0579-0 10.2307/2533446 10.1101/2021.04.27.21256193 10.1038/s41591-021-01446-y 10.1038/s41591-021-01490-8 10.1016/j.cct.2006.04.004 10.1056/NEJMoa2101544 10.1186/1471-2288-14-25
ContentType	Journal Article
Copyright	The Author(s) 2022 2022. The Author(s). COPYRIGHT 2022 BioMed Central Ltd. 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml	– notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: COPYRIGHT 2022 BioMed Central Ltd. – notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID	C6C AAYXX CITATION NPM IOV ISR 3V. 7QL 7T2 7U9 7X7 7XB 88E 8C1 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BENPR C1K CCPQU COVID DWQXO FYUFA GHDGH H94 K9. M0S M1P M7N PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA
DOI	10.1186/s12879-022-07418-y
DatabaseName	Springer Nature OA Free Journals CrossRef PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Health and Safety Science Abstracts (Full archive) Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central Environmental Sciences and Pollution Management ProQuest One Community College Coronavirus Research Database ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts Health & Safety Science Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	PubMed Publicly Available Content Database MEDLINE - Academic
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Public Health
EISSN	1471-2334
EndPage	12
ExternalDocumentID	oai_doaj_org_article_3a6b90100860400dabc4f294383cb660 PMC9077344 A702840991 35525973 10_1186_s12879_022_07418_y
Genre	Journal Article
GeographicLocations	United States United States--US
GeographicLocations_xml	– name: United States – name: United States--US
GroupedDBID	--- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8C1 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR IOV ISR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB AAYXX AFFHD CITATION ALIPV NPM 3V. 7QL 7T2 7U9 7XB 8FK AZQEC C1K COVID DWQXO H94 K9. M7N PKEHL PQEST PQUKI PRINS 7X8 5PM
ID	FETCH-LOGICAL-c675t-d108b72ee88f294ca5012ae0d36bad7e22d25b1727f74d9f10e443227b424d863
IEDL.DBID	BENPR
ISICitedReferencesCount	188
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000791920900002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1471-2334
IngestDate	Mon Nov 10 04:34:50 EST 2025 Tue Nov 04 01:48:58 EST 2025 Fri Sep 05 08:34:35 EDT 2025 Mon Oct 06 18:26:59 EDT 2025 Tue Nov 11 10:26:32 EST 2025 Tue Nov 04 17:34:13 EST 2025 Thu Nov 13 14:29:18 EST 2025 Thu Nov 13 15:22:04 EST 2025 Mon Jul 21 06:00:21 EDT 2025 Sat Nov 29 04:42:23 EST 2025 Tue Nov 18 22:28:18 EST 2025 Sat Sep 06 07:26:49 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	COVID-19 Waning immunity Vaccine effectiveness
Language	English
License	2022. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c675t-d108b72ee88f294ca5012ae0d36bad7e22d25b1727f74d9f10e443227b424d863
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3
OpenAccessLink	https://www.proquest.com/docview/2666409280?pq-origsite=%requestingapplication%
PMID	35525973
PQID	2666409280
PQPubID	42582
PageCount	12
ParticipantIDs	doaj_primary_oai_doaj_org_article_3a6b90100860400dabc4f294383cb660 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9077344 proquest_miscellaneous_2661086231 proquest_journals_2666409280 gale_infotracmisc_A702840991 gale_infotracacademiconefile_A702840991 gale_incontextgauss_ISR_A702840991 gale_incontextgauss_IOV_A702840991 pubmed_primary_35525973 crossref_citationtrail_10_1186_s12879_022_07418_y crossref_primary_10_1186_s12879_022_07418_y springer_journals_10_1186_s12879_022_07418_y
PublicationCentury	2000
PublicationDate	2022-05-07
PublicationDateYYYYMMDD	2022-05-07
PublicationDate_xml	– month: 05 year: 2022 text: 2022-05-07 day: 07
PublicationDecade	2020
PublicationPlace	London
PublicationPlace_xml	– name: London – name: England
PublicationTitle	BMC infectious diseases
PublicationTitleAbbrev	BMC Infect Dis
PublicationTitleAlternate	BMC Infect Dis
PublicationYear	2022
Publisher	BioMed Central BioMed Central Ltd Springer Nature B.V BMC
Publisher_xml	– name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC
References	MJ Page (7418_CR5) 2021; 372 VJ Hall (7418_CR25) 2021; 397 EJ Haas (7418_CR17) 2021; 397 ET Chin (7418_CR32) 2021; 385 C Paris (7418_CR33) 2021; 27 LR Baden (7418_CR3) 2021; 384 R DerSimonian (7418_CR11) 2007; 28 E Mathieu (7418_CR1) 2021; 27 N Dagan (7418_CR23) 2021; 384 N Andrews (7418_CR41) 2022; 386 N Andrews (7418_CR38) 2021; 397 H Chemaitelly (7418_CR20) 2021; 27 WH Self (7418_CR30) 2021; 70 J IntHout (7418_CR13) 2014; 14 AM Methley (7418_CR6) 2014; 14 SL Hughes (7418_CR34) 2020; 38 MW Tenforde (7418_CR28) 2021; 326 J Sadoff (7418_CR4) 2021; 384 M Egger (7418_CR15) 1997; 315 YM Bar-On (7418_CR36) 2021; 385 T Patalon (7418_CR37) 2021; 384 K Sidik (7418_CR12) 2006; 50 RW Frenck Jr (7418_CR31) 2021; 385 7418_CR24 7418_CR27 FP Polack (7418_CR2) 2020; 383 7418_CR40 7418_CR9 7418_CR8 7418_CR7 JP Higgins (7418_CR14) 2003; 327 HM El Sahly (7418_CR19) 2021; 385 K Ali (7418_CR29) 2021; 385 N Barda (7418_CR39) 2021; 398 SJ Thomas (7418_CR21) 2021; 385 H Chemaitelly (7418_CR22) 2021; 11 SY Tartof (7418_CR18) 2021; 398 HM Scobie (7418_CR35) 2021; 70 GH Guyatt (7418_CR10) 2008; 336 N Dagan (7418_CR26) 2021; 27 CB Begg (7418_CR16) 1994; 50
References_xml	– volume: 372 year: 2021 ident: 7418_CR5 publication-title: BMJ doi: 10.1136/bmj.n71 – volume: 398 start-page: 2093 year: 2021 ident: 7418_CR39 publication-title: The Lancet doi: 10.1016/S0140-6736(21)02249-2 – volume: 27 start-page: 1 year: 2021 ident: 7418_CR1 publication-title: Nat Human Behav – volume: 50 start-page: 3681 issue: 12 year: 2006 ident: 7418_CR12 publication-title: Comput Stat Data Anal doi: 10.1016/j.csda.2005.07.019 – volume: 385 start-page: 2300 year: 2021 ident: 7418_CR32 publication-title: New Engl J Med doi: 10.1056/NEJMc2114089 – volume: 397 start-page: 1646 year: 2021 ident: 7418_CR38 publication-title: Medrxiv – volume: 385 start-page: 239 year: 2021 ident: 7418_CR31 publication-title: New Engl J Med doi: 10.1056/NEJMoa2107456 – ident: 7418_CR27 – volume: 386 start-page: 1532 year: 2022 ident: 7418_CR41 publication-title: New Engl J Med doi: 10.1056/NEJMoa2119451 – volume: 27 start-page: 1699 issue: 11 year: 2021 ident: 7418_CR33 publication-title: Clin Microbiol Infect doi: 10.1016/j.cmi.2021.06.043 – volume: 384 start-page: 403 issue: 5 year: 2021 ident: 7418_CR3 publication-title: N Engl J Med doi: 10.1056/NEJMoa2035389 – volume: 11 start-page: 6233 year: 2021 ident: 7418_CR22 publication-title: New Engl J Med – ident: 7418_CR9 – volume: 384 start-page: 1412 issue: 15 year: 2021 ident: 7418_CR23 publication-title: N Engl J Med doi: 10.1056/NEJMoa2101765 – volume: 385 start-page: 2241 year: 2021 ident: 7418_CR29 publication-title: New Engl J Med doi: 10.1056/NEJMoa2109522 – volume: 336 start-page: 924 issue: 7650 year: 2008 ident: 7418_CR10 publication-title: BMJ doi: 10.1136/bmj.39489.470347.AD – volume: 385 start-page: 1774 year: 2021 ident: 7418_CR19 publication-title: New Engl J Med doi: 10.1056/NEJMoa2113017 – volume: 326 start-page: 2043 year: 2021 ident: 7418_CR28 publication-title: JAMA doi: 10.1001/jama.2021.19499 – volume: 70 start-page: 1284 issue: 37 year: 2021 ident: 7418_CR35 publication-title: Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm7037e1 – ident: 7418_CR8 doi: 10.1002/9780470712184.ch8 – volume: 383 start-page: 2603 year: 2020 ident: 7418_CR2 publication-title: New Engl J Med doi: 10.1056/NEJMoa2034577 – volume: 315 start-page: 629 issue: 7109 year: 1997 ident: 7418_CR15 publication-title: BMJ doi: 10.1136/bmj.315.7109.629 – volume: 398 start-page: 1407 issue: 10309 year: 2021 ident: 7418_CR18 publication-title: The Lancet doi: 10.1016/S0140-6736(21)02183-8 – volume: 70 start-page: 1337 issue: 38 year: 2021 ident: 7418_CR30 publication-title: Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm7038e1 – volume: 397 start-page: 1819 issue: 10287 year: 2021 ident: 7418_CR17 publication-title: The Lancet doi: 10.1016/S0140-6736(21)00947-8 – volume: 327 start-page: 557 issue: 7414 year: 2003 ident: 7418_CR14 publication-title: BMJ doi: 10.1136/bmj.327.7414.557 – volume: 385 start-page: 1761 year: 2021 ident: 7418_CR21 publication-title: New Engl J Med doi: 10.1056/NEJMoa2110345 – volume: 385 start-page: 1393 issue: 15 year: 2021 ident: 7418_CR36 publication-title: N Engl J Med doi: 10.1056/NEJMoa2114255 – volume: 38 start-page: 460 issue: 3 year: 2020 ident: 7418_CR34 publication-title: Vaccine doi: 10.1016/j.vaccine.2019.10.090 – volume: 397 start-page: 1725 issue: 10286 year: 2021 ident: 7418_CR25 publication-title: The Lancet doi: 10.1016/S0140-6736(21)00790-X – volume: 14 start-page: 1 issue: 1 year: 2014 ident: 7418_CR6 publication-title: BMC Health Serv Res doi: 10.1186/s12913-014-0579-0 – volume: 50 start-page: 1088 year: 1994 ident: 7418_CR16 publication-title: Biometrics doi: 10.2307/2533446 – ident: 7418_CR40 – ident: 7418_CR7 – ident: 7418_CR24 doi: 10.1101/2021.04.27.21256193 – volume: 27 start-page: 1614 issue: 9 year: 2021 ident: 7418_CR20 publication-title: Nat Med doi: 10.1038/s41591-021-01446-y – volume: 27 start-page: 1693 issue: 10 year: 2021 ident: 7418_CR26 publication-title: Nat Med doi: 10.1038/s41591-021-01490-8 – volume: 384 start-page: 403 year: 2021 ident: 7418_CR37 publication-title: medRxiv – volume: 28 start-page: 105 issue: 2 year: 2007 ident: 7418_CR11 publication-title: Contemp Clin Trials doi: 10.1016/j.cct.2006.04.004 – volume: 384 start-page: 2187 issue: 23 year: 2021 ident: 7418_CR4 publication-title: New Engl J Med doi: 10.1056/NEJMoa2101544 – volume: 14 start-page: 1 issue: 1 year: 2014 ident: 7418_CR13 publication-title: BMC Med Res Methodol doi: 10.1186/1471-2288-14-25
SSID	ssj0017829
Score	2.6678946
Snippet	Background The temporal evolution of SARS-CoV-2 vaccine efficacy and effectiveness (VE) against infection, symptomatic, and severe COVID-19 is incompletely... The temporal evolution of SARS-CoV-2 vaccine efficacy and effectiveness (VE) against infection, symptomatic, and severe COVID-19 is incompletely defined. The... Background The temporal evolution of SARS-CoV-2 vaccine efficacy and effectiveness (VE) against infection, symptomatic, and severe COVID-19 is incompletely... Abstract Background The temporal evolution of SARS-CoV-2 vaccine efficacy and effectiveness (VE) against infection, symptomatic, and severe COVID-19 is...
SourceID	doaj pubmedcentral proquest gale pubmed crossref springer
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	439
SubjectTerms	Age Bias Clinical trials Coronaviruses COVID-19 COVID-19 vaccines Estimates Evolution Infections Infectious Diseases Internal Medicine Literature reviews Medical Microbiology Medicine Medicine & Public Health Meta-analysis mRNA vaccines Parasitology Public health Quality assessment Risk assessment Severe acute respiratory syndrome coronavirus 2 Tropical Medicine Vaccination Vaccine effectiveness Vaccine efficacy Vaccines Viral diseases Waning immunity Web portals
SummonAdditionalLinks	– databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELfQhBAviG8CAxmExAOzlrhpbPNWChN7YEMrVHuzHNvZKrF0atpJ5a_nznG6ZWjwwmt8kZz7ne9DOf-OkLdlnqXKZYalhcIRZpVjJURtJuww9d4qx7kLwybEwYE8Plbfroz6wp6wlh64VdzuwBQlthBA6o325kxp84orZNi0ZVGEah2ynq6Yiv8PIO6p7oqMLHYb8MJCMexcxxAq2boXhgJb_58--UpQut4wee2vaQhGe_fJvZhF0lG7-wfklq8fkjtf43_yR-TXZHQ0YeP5lHF6YSw-pG3nRnRu1JyYGWSGtGvGqndosz47X84DhSs1taMQM_3C0_HhdP8Ty9QHaugl7zNt77wEwTO_NMxEdpPH5Mfe5-_jLyxOWWAWioUlc1kqS8G9lxL1iiMSMm586gZFaZzwABYflpjnVCJ3qspSn-fgBgRgmjtZDJ6QrXpe-2eEZhXEw8IPTW7S3EorHYDFAf8085YPBwnJOqVrGynIcRLGTx1KEVnoFigNQOkAlF4n5P3mnfOWgOOv0h8Ry40kkmeHB2BSOpqU_pdJJeQNWoJGeowa-29OzKpp9P7hVI8E5GNQEqvsJqHJUU_oXRSq5vCh1sQ7D6AupN3qSW73JOGQ2_5yZ5U6OplGQ25VwCqXsOPXm2V8Exvnaj9fBRmcpQVZfEKetka8UQ6kmlD8CoBF9My7p73-Sj07DRTkKhVikOcJ2ekOwuW2bkbn-f9A5wW5y8NBHsJZ3iZby8XKvyS37cVy1ixeBTfwGzo5W_Y priority: 102 providerName: Directory of Open Access Journals – databaseName: Springer LINK dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagIMSFNzRQkEFIHKjVvG1zWxYqeqBFu7DqzXJsZ1mpTarNbqXl1zN2nJQUigRXeyzZ43nK428Qel2kUch1JEmYc9vCrNSkAK9NqMpCYxTXcaxdswl6eMiOj_kX_yms6arduydJZ6mdWrN8rwFLSjmx1efWDTKyuY5ugLtjVh0n01n_dgA-j3ffY_64buCCHFL_7_b4F4d0uVjy0oupc0T7d__vCPfQHR944lErKffRNVM9QLc--6f1h-jHdDSZknE9IzE-l8oO4rbYw9tDLOdyAcEk7uq3ql3cbE7PVrVDfcWy0hjcrFkaPD6aHXwgEX-HJb6AisbtNxlHeGpWkkgPiPIIfdv_-HX8ifjGDERBfrEiOgpZQWNjGCtjntquClEsTaiTvJCaGrjfOCtsaFTSVPMyCk2aguWgIAapZnnyGG1VdWW2EY5KcKG5yWQqw1QxxXShwEWWOoyMirMkQFF3V0J51HLbPONEuOyF5aJlqgCmCsdUsQnQ237NWYvZ8Vfq91YEekqLt-0G6uVcePUVicwLW8gCCaC1elrCLu3RIb9XRZ6HAXplBUhYRI3KluzM5bppxMHRTIwohHCQRfPoKqLpZED0xhOVNRxUSf9NAthlkboGlDsDSrALajjdCbPwdqkREI7lMBsz2PHLftqutLV2lanXjsa234LAP0BPWtnvmQPRKeTLFK6FDrRiwL3hTLX47lDLeUhpkqYB2u1042JbV9_O038jf4Zux069MtCwHbS1Wq7Nc3RTna8WzfKFsxM_ASNeYko priority: 102 providerName: Springer Nature
Title	SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis
URI	https://link.springer.com/article/10.1186/s12879-022-07418-y https://www.ncbi.nlm.nih.gov/pubmed/35525973 https://www.proquest.com/docview/2666409280 https://www.proquest.com/docview/2661086231 https://pubmed.ncbi.nlm.nih.gov/PMC9077344 https://doaj.org/article/3a6b90100860400dabc4f294383cb660
Volume	22
WOSCitedRecordID	wos000791920900002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVADU databaseName: BioMed Central Open Access Free customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: 8C1 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: RSV dateStart: 20011201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFLZYhxAS4jJuhVEZhMQDs5ZbY4cX1JVN9GFb1ULVPVmO7ZRKLClNO6n8eo4dtyVD2wsvkRyfSLHPzcc-_g5C79PI9xLlC-LFiSlhlimSgtcmVLY9rWWigkDZYhP07IyNx0nfbbiVLq1ybROtoVaFNHvkh-BIYohFAuZ9nv0ipmqUOV11JTR20K5BKosaaPfo-Kw_2JwjgP9L1ldlWHxYgjWmCTEZ7MaVMrKquSOL2v-vbf7LOV1PnLx2emqd0smj_x3OY_TQLUdxp5KfJ-iOzvfQvVN34L6HHlTberi6rfQU_R52BkPSLUYkwFdCGiJcpYQ4q4nFRExhyYnXWV75AS5Xl7NFYbFhscgVBmes5xp3z0e9L8RPPmGBt4DSuLpMYwkv9UIQ4WBTnqHvJ8fful-JK99AJEQhC6J8j6U00JqxLEgiU3vBD4T2VBinQlENUhC0U7OAymikksz3dBSBfaEgLJFicfgcNfIi1y8R9jNwtLFui0h4kWSSqVSCI82U52sZtMMm8tdc5NJhm5sSGz-5jXFYzCvOc-A8t5znqyb6uPlmViF73Ep9ZIRjQ2lQue2LYj7hTsl5KOLUpLtAmGhsoxLwl2boIQtlGsdeE70zosUN7kZuEnsmYlmWvHc-4h0KCz0QiMS_iWg4qBF9cERZAQOVwl2mgOkyeF41yv0aJVgPWe9eyyd31qvkW-FsorebbvOlycjLdbG0NKZIF4QHTfSi0orN5MAaFqJqCmyhNX2pzV69J5_-sNjmiUdpGEVNdLDWrO1v3cydV7eP4jW6H1idb4Pa76PGYr7Ub9BdebWYlvMW2qFjap8Mnqzrt5wVadkNGmj1e6f9C2gNhqM_YGp37Q
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3db9MwELdGhwAJ8TG-AgMMAvHArCVOmjhICJWOadXWrVpHNZ6MYzulEktK0w6VP4q_kXM-WjK0ve2B1_gS2ee7-93F5zuEXkWeY4fKEcT2Q9PCLFYkAtQmgWzaWstQUaryZhPB_j47Pg57K-h3dRfGpFVWNjE31CqV5h_5JgCJD7EIZfaH8Q9iukaZ09WqhUYhFrt6_hNCtux9Zwv29zWl25-O2juk7CpAJDjHU6Icm0UB1ZqxmIaeaQngUKFt5fqRUIGGydFmZHA9DjwVxo6tPQ_EPoA1eIr5Lnz3Clr1QNhZA632Ot3el8W5BeBtWF3NYf5mBtY_CInJmDfQzci8Bn95l4B_seAvMDybqHnmtDYHwe3b_xv77qBbpbuNW4V-3EUrOllD17plQsEauln8tsTFbax76Fe_ddgn7XRAKD4V0hDhIuWlRAUshmIELjWustiSDZzNT8bTNK99i0WiMDgbeqJx-2DQ2SJO-A4LvCyYjYvLQjnhiZ4KIsqyMPfR50vhxAPUSNJEP0LYicGR8HVTeML2JJNMRRIchVjZjpa06VrIqaSGy7J2u2kh8p3nMRzzeSFpHCSN55LG5xZ6u3hnXFQuuZD6oxHGBaWpOp4_SCdDXhox7go_Muk8EAYb268EzNIs3WWujHzfttBLI8rc1BVJTOLSUMyyjHcOBrwVgCMLAhg65xH1D2tEb0qiOIWFSlFeFgF2mXplNcr1GiVYR1kfrvSBl9Y540tlsNCLxbB502QcJjqd5TSmCRmEPxZ6WGjhgjngo1MIxGFbgpp-1rhXH0lG3_La7aEdBK7nWWij0uTltM7fnccXr-I5ur5z1N3je5393SfoBs3tTRNMzjpqTCcz_RRdlafTUTZ5VtorjL5eto7_AXH0zSs
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdgoIkXvgeFAQYh8cCsJakbJ7yVjooK6KYVqr1Zju2USiypmnRS-eu5c5JuGQwJ8WqfJft8n_L5d4S8TrjvxcZXzAtjbGGWGpaA12ZC9zxrdWyCwLhmE2I8jk5O4qMLv_hdtXvzJFn9aUCUpqzcX5i0UvEo3C_AqoqYYSU6usSIra-TGxybBmG-Pplu3hHA_8XNV5k_rmu5I4fa_7ttvuCcLhdOXno9dU5peOf_j3OX3K4DUtqvJOgeuWaz-2T7S_3k_oD8nPSPJ2yQT1lAz5TGQVoVgdR2kqqZmkOQSZu6rmyPFuvTRZk7NFiqMkPB_dqlpYPD6eiA-fE7qug5hDStvs84wlNbKqZqoJSH5Nvww9fBR1Y3bGAa8o6SGbiBRATWRlEaxBy7LfiBsp7phokywsK9B70EQ6ZUcBOnvmc5B4siQDy4icLuDtnK8sw-JtRPwbWGtqe48riOdGQSDa4zNZ5vddDrdojf3JvUNZo5NtX4IV1WE4WyYqoEpkrHVLnukLebNYsKy-Ov1O9RHDaUiMPtBvLlTNZqLbsqTLDABSQPraFRsEs8OuT9OglDr0NeoTBJRNrIsJRnplZFIUeHU9kXENpBdh37VxFNjltEb2qiNIeDalV_nwB2IYJXi3K3RQn2QrenG8GWtb0qJIRpIcwGEez45WYaV2INXmbzlaNBDYOEoEMeVXqwYQ5ErZBHC7gW0dKQFvfaM9n8u0Mzjz0hupx3yF6jJ-fbuvp2nvwb-QuyfXQwlJ9H409Pya3AaVoPlG2XbJXLlX1Gbuqzcl4snzvz8Qv6Bm4S
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=SARS-CoV-2+vaccine+effectiveness+against+infection%2C+symptomatic+and+severe+COVID-19%3A+a+systematic+review+and+meta-analysis&rft.jtitle=BMC+infectious+diseases&rft.au=Ssentongo%2C+Paddy&rft.au=Ssentongo%2C+Anna+E&rft.au=Voleti%2C+Navya&rft.au=Groff%2C+Destin&rft.date=2022-05-07&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2334&rft.eissn=1471-2334&rft.volume=22&rft.issue=1&rft_id=info:doi/10.1186%2Fs12879-022-07418-y&rft.externalDBID=ISR&rft.externalDocID=A702840991
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2334&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2334&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2334&client=summon